2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (September 2015) - Van Cutsem, E.; Obermannova, R.; Bodoky, G.; Prausová, J.; García-Carbonero, R.; Ciuleanu, T.; Alfonso, P Garcia; Portnoy, D.; Cohn, A.; Yamazaki, K.; Clingan, P; Yoshino, T.; et al.